Trial Profile
Open-label, Multicenter, Interventional, Dose Titration Study to Assess the Long-term Study of CS-3150 2.5mg and 5mg Alone as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Aug 2022
Price :
$35
*
At a glance
- Drugs Esaxerenone (Primary) ; Antihypertensives; Calcium channel antagonists
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 17 Aug 2022 Results of post hoc substudy (n=25) assessing esaxerenone monotherapy and its long-term antihypertensive effect and urinary biomarkers published in the Advances in Therapy
- 10 Aug 2017 Status changed from active, no longer recruiting to completed.
- 14 Feb 2017 Status changed from recruiting to active, no longer recruiting.